Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
| Stock | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| CRBGCorebridge Financial, Inc. | Nippon Life Insurance Co10% Owner | $12.1M | Added | |||
| Purchased under a Rule 10b5-1 plan. Weighted avg price $34.71 (range $34.31–$35.07). Post-transaction position: ~129.85M shares. Strategic long-term investor in AIG life/annuity spinoff. | ||||||
| LEOBNY Mellon Strategic Municipals, Inc. | Saba Capital Management, L.P. (Boaz R. Weinstein)10% Owner | $1.92M | Added | |||
| Bought across 3 sessions (Oct 16–19) at ~$5.65 avg. Post-buy position: 6,428,634 shares. Part of Saba's ongoing closed-end fund discount arbitrage campaign. Current price $5.73 (+1.3%). | ||||||
| DSMBNY Mellon Strategic Municipal Bond Fund, Inc. | Saba Capital Management, L.P.10% Owner | $1.10M | Added | |||
| Three tranches: 48,135 @ $5.26, 90,507 @ $5.28, 69,080 @ $5.29 (Oct 16–19). Weighted avg ~$5.278. Current price $5.31 (+0.6%). Part of Saba's CEF discount campaign. | ||||||
| JOFJapan Smaller Capitalization Fund Inc | Saba Capital Management, L.P.10% Owner | $552K | Added | |||
| Two tranches: 16,222 @ $11.94 (Oct 16) and 30,000 @ $11.94 (Oct 19). Weighted avg $11.94. Post-buy: 2,742,376 shares. Current price $11.83 (−0.9%). Part of Saba CEF campaign. | ||||||
| ECFEllsworth Growth & Income Fund Ltd | Saba Capital Management, L.P.10% Owner | $386K | Added | |||
| Two tranches: 16,347 @ $11.65 (Oct 16) and 17,079 @ $11.47 (Oct 19). Weighted avg ~$11.558. Current price $11.46 (−0.9%). Part of Saba CEF campaign. | ||||||
| BOLDBoundless Bio, Inc. | Kevin Tang / Tang Capital Management LLC10% Owner | $350K | Added | |||
| Four tranches Oct 16–20 at ~$2.33–$2.37 avg. Weighted avg ~$2.339. Current price $2.43 (+3.9%). Tang Capital is a serial biotech deep-value activist. Boundless Bio is a small-cap oncology company. | ||||||
| GFNew Germany Fund Inc | Saba Capital Management, L.P.10% Owner | $311K | Added | |||
| Two tranches: 15,042 @ $10.31 (Oct 16) and 15,046 @ $10.34 (Oct 19). Weighted avg ~$10.325. Current price $10.43 (+1.0%). Part of Saba CEF discount campaign. | ||||||
Scanned the last 24 hours of EDGAR Form 4 filings. 7 qualifying buys (≥ $250K, transaction type P) totalling $16.7M.
Dominant theme: Saba Capital's closed-end fund discount campaign. Boaz Weinstein's Saba Capital Management accounts for 5 of the 7 qualifying buys ($4.16M combined), continuing its systematic accumulation across BNY Mellon and other closed-end funds trading at discounts to NAV — LEO, DSM, JOF, ECF, and GF. This is a continuation of Saba's well-known activist CEF strategy.
Largest single buy: Nippon Life / Corebridge Financial (CRBG) — $12.05M. Nippon Life is a long-term strategic investor in Corebridge (the AIG life/annuity spinoff). This purchase was executed under a Rule 10b5-1 plan and lifts their position to ~129.85M shares (~26% stake). Life insurance / annuity sector continues to attract institutional conviction.
Biotech conviction buy: Boundless Bio (BOLD) — $349.6K. Kevin Tang's Tang Capital accumulated another 149,474 shares of this small-cap oncology company at ~$2.34, with the stock now trading at $2.43 (+3.9%). Tang is a serial biotech activist known for taking deep-value positions at distressed biotechs.
Market was pre-open at scan time (7:14 AM ET); all prices are from the prior session close or latest tick.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.